Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD

In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).

i3 Health is pleased to partner with the National Breast Cancer Foundation^® (NBCF) for ODACon 2022. Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now^® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 16 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient support programs. For more information, please visit https://www.nationalbreastcancer.org.

Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD

At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the...

Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD

The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 2

In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, sup...

Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD

Oncology Data Advisor™ · Highlights from the San Antonio Breast Cancer Symposium At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of pa...

Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD

Oncology Data Advisor™ · Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobu...

The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker

Oncology Data Advisor™ · The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metas...

Abemaciclib With Endocrine Therapy Receives Expanded Approval for Early Breast Cancer

The FDA has granted approval to abemaciclib (Verzenio®, Eli Lilly and Company) with endocrine therapy—tamoxifen or an aromatase inhibitor—for treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (H...

Sacituzumab Govitecan-hziy Approved for HR-Positive Breast Cancer

The FDA has granted approval to sacituzumab govitecan-hziy (Trodelvy®, Gilead Sciences, Inc.) for treatment of unresectable, locally advanced, or metastatic hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative brea...

Elacestrant Approved for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer

The FDA has approved elacestrant (Orserdu™, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative, estrogen receptor 1 (ESR1)–mutated advanced...